abstract |
Monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing are provided that bind to and inhibit c-Met activity and which are effective in the treatment of cancer tumors and other diseases, disorders or conditions whose pathogenesis is mediated by c-Met. |